Business EconomyPosted at: Dec 13 2025 4:02AM


Ozempic ® - world’s most prescribed GLP-1is now available in India

Hyderabad, Dec 12 (UNI) Novo Nordisk, a global healthcare company, on Friday announced the launch of its once-weekly diabetes drug Ozempic® (injectable semaglutide) in India, marking a significant addition to the country’s treatment options for type 2 diabetes.
The therapy, a GLP-1 receptor agonist, is approved as an adjunct to diet and exercise for adults with uncontrolled type 2 diabetes mellitus (T2DM).
The introduction of Ozempic® comes at a critical time for India, which, according to WHO’s 2023–24 estimates, has 101 million people living with diabetes—about 11.4% of the population—along with 136 million individuals with prediabetes and 254 million with generalised obesity, the Denmark based healthcare company said in a release here.
The growing metabolic health burden has heightened the need for effective and evidence-based interventions.
Ozempic® has shown strong clinical outcomes, including substantial reductions in HbA1c levels and notable weight-loss benefits. It is suitable for adults with HbA1c levels of 7% or higher, including those with elevated cardiovascular risk or existing cardiovascular disease.
Clinical evidence also indicates a reduction in cardiovascular events and protection against the progression of chronic kidney disease, making the drug a comprehensive option for long-term diabetes management.
Calling the launch a major milestone, Vikrant Shrotriya, Managing Director of Novo Nordisk India, said the therapy brings global clinical trust and proven performance to Indian patients.
He emphasized that the once-weekly delivery through an easy-to-use pen device offers meaningful improvements in glycaemic control, weight management and cardiovascular and kidney outcomes.
Ozempic® works by mimicking the action of the natural hormone GLP-1, helping regulate blood sugar, reduce appetite and support weight loss in people with type 2 diabetes.
With a long-standing global safety profile and more than 38 million patient-years of clinical use, semaglutide was recently added to the World Health Organisation’s Model List of Essential Medicines, underscoring its growing importance in diabetes and obesity care.
The drug is now available in India in 0.25 mg, 0.5 mg and 1 mg strengths via the FlexTouch® pen, enabling doctors to tailor dosing to each patient’s needs for effective, sustained diabetes control.
Ozempic® is a GLP-1 receptor agonist that helps: Improve glycaemic control and reduce HbA1c; Regulate appetite and food intake by acting on areas of the brain that control hunger besides supporting weight loss in people with T2DM.
The use of this medication is strictly contingent upon a licensed healthcare provider’s prescription and clinical judgment.
Always consult your healthcare professional for medical advice and treatment options tailored to your individual needs, it said.
UNI KNR RN
Please log in to get detailed story.
Tags: #Ozempic ® - world’s most prescribed GLP-1is now available in India
More News

NITES complains to Centre over Wipro hiring

19 Jan 2026 | 9:41 PM

Bengaluru, Jan 19 (UNI) The Nascent Information Technology Employees Senate (NITES) has formally submitted a complaint to the union Labour Minister Mansukh L Mandaviya against Wipro Limited, citing serious recruitment irregularities affecting over 250 selected fresh graduates across multiple states.

see more..

New IBM platforms lets businesses, govts control AI workloads locally

19 Jan 2026 | 9:25 PM

Bengaluru, Jan 19 (UNI) IBM has launched a new software called IBM Sovereign Core, designed to help businesses, governments, and service providers manage AI workloads securely while keeping full control over their technology.

see more..

UP secures Rs 9,750 cr MoUs at Davos

19 Jan 2026 | 9:16 PM

Davos/ Lucknow, Jan 19 (UNI) The Uttar Pradesh Government delegation, led by state finance and parliamentary affairs Minister Suresh Kumar Khanna, began its engagements at the World Economic Forum (WEF) meeting in Davos with a strong focus on forging global partnerships and securing high-impact investments.

see more..

Arya Omnitalk CEO backs CCPA crackdown on illegal walkie-talkies

19 Jan 2026 | 9:13 PM

Bengaluru, Jan 19 (UNI) The Central Consumer Protection Authority's (CCPA) crackdown on the illegal sale of walkie-talkies on e-commerce platforms is timely and essential to protect both consumer safety and national security, Arya Omnitalk CEO Paresh Shetty said on Monday.

see more..

Nifty falls below 25,500 amid weak global cues

19 Jan 2026 | 7:37 PM

New Delhi, Jan 19 (UNI) The Indian stock market on Monday began the week on a subdued note. Nifty fell below 25,500 intraday amid weak global cues triggering broad-based profit booking.

see more..